Please login to the form below

Not currently logged in
Email:
Password:

liver cancer

This page shows the latest liver cancer news and features for those working in and with pharma, biotech and healthcare.

Positive first-line phase 3 results for Tecentriq

Positive first-line phase 3 results for Tecentriq

If Tecentriq can meet the secondary endpoints of the study as a first-line treatment, the drug could see Roche establish dominance in the bladder cancer market. ... results from the use of Tecentriq in a wider population of people with bladder cancer,

Latest news

More from news
Approximately 10 fully matching, plus 116 partially matching documents found.

Latest Intelligence

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    This public-private research alliance is aimed at improving survival rates in hepatocellular carcinoma (the primary cancer of the liver). ... of this cancer.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Co-development was another area in which major pharma firms were active, particularly Lilly, which enlarged its work with Boehringer Ingelheim to add in breast cancer programmes and closed a ... NASH and biosimilars. One therapeutic indication that could

  • Pharma deals in April 2015 Pharma deals in April 2015

    The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid. ... Menarini AP will be responsible for the clinical development, regulatory approval and commercialisation of resminostat in all oncological

  • Pharma deals during September 2013 Pharma deals during September 2013

    The lead pipeline candidates are SGI-110, a subcutaneous hypomethylating agent in multiple studies for a variety of haematological and solid tumour oncology indications, including MDS, AML, ovarian cancer and liver ... cancer, and AT13387, a second

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics